密歇根州安阿伯 - Esperion（纳斯达克股票代码：ESPR）今天宣布，该公司已向加拿大卫生部提交了两种降低胆固醇药物NEXLETOL和NEXLIZET的新药申请。过去12个月，Esperion的收入增长了187%。这两种口服非他汀类药物旨在降低低密度脂蛋白胆固醇（LDL-C）和心血管风险。

Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

密歇根州安阿伯 - Esperion (NASDAQ:ESPR) 宣布，其合作伙伴大塚制药株式会社已向日本厚生劳动省提交了bempedoic acid的新药申请（NDA），该药物用于治疗高胆固醇血症和家族性高胆固醇血症患者。这种在肝脏中抑制胆固醇合成酶的药物已在美国和欧洲上市。

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale of bempedoic acid in Japan for the treatment of ...

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination ...

Known as a non-statin lipid-lowering treatment option taken orally, bempedoic acid is a new class of drug for treating high LDL-cholesterol conditions indicative of cardiovascular diseases.